Drugs / Renzapride
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00607971 | Apr 2006 → Jun 2008 | irritable bowel syndrome | Alizyme | Terminated | No outcome recorded |
| Phase 3 | NCT00268879 | Dec 2005 → Jan 2008 | irritable bowel syndrome | Alizyme | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Renzapride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00268879 ↗ |
| Known as | ATL-1251 | ChEMBL registry synonym — accepted as the source's own label CHEMBL296522 ↗ |
| Known as | BRL 24924A | ChEMBL registry synonym — accepted as the source's own label CHEMBL296522 ↗ |
| Known as | Brl-24924 | ChEMBL registry synonym — accepted as the source's own label CHEMBL296522 ↗ |
| Known as | Renzaprida | ChEMBL registry synonym — accepted as the source's own label CHEMBL296522 ↗ |
| Action | Activate | “Serotonin 4 (5-HT4) receptor agonist” CHEMBL296522 ↗ |
| Modality | Small molecule | — CHEMBL296522 ↗ |
| Route | Oral | “Two capsules are taken by mouth each morning and each evening” NCT00268879 ↗ |
| Target | HTR4 | “Serotonin 4 (5-HT4) receptor agonist” CHEMBL296522 ↗ |